[26], loss of normal p53 function results in resistance to ALK‐TKIs in ALK+ NSCLC and combined proteasome inhibitor with alectinib is a promising therapy for ALK+TP53 NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.